Clinical outcomes of de novo metastatic HER2-low breast cancer: a National Cancer Database Analysis

The development of novel anti-HER2 drugs opens new treatment options for women with breast cancers, including lower expression of HER2. The epidemiology and clinical outcome of metastatic HER2-low breast cancer remain not well described. We designed a retrospective cohort study of the 2010–2017 Nati...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Changchuan, Perimbeti, Stuthi, Deng, Lei, Shapiro, Charles L., Gandhi, Shipra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803673/
https://www.ncbi.nlm.nih.gov/pubmed/36585415
http://dx.doi.org/10.1038/s41523-022-00498-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803673/
https://www.ncbi.nlm.nih.gov/pubmed/36585415
http://dx.doi.org/10.1038/s41523-022-00498-8

Ejemplares similares